✉ The Friday AI Brief: the week's 5 best AI stories, tools & comparisons — in your inbox every Friday morning.

Science Corporation co-founder and CEO Max Hodak speaking at TechCrunch Disrupt

Science Corporation Raises $400 Million at a $3.5 Billion Valuation to Bring Its Vision Chip to the US

November 17, 2026 — Science Corporation, the neural-interface company founded by former Neuralink president Max Hodak, has raised a $400 million Series D that values the company at $3.5 billion, according to a person familiar with the deal. Why it matters: unlike most brain-tech valuations, this one is backed by a product already approved and selling in Europe — a chip that restores some vision to people going blind.

What happened

Science announced the $400 million Series D in a company blog post today. Backers include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech. The $3.5 billion valuation was reported by TechCrunch from a person familiar with the deal; the company confirmed the round size and a lifetime fundraising total of more than $900 million since its 2021 founding. The step up is steep: the company’s Series C in March 2026 raised $230 million at a reported valuation of about $1.5 billion.

The product behind the money

Science’s first product is PRIMA, a wearable-and-implantable system built around a tiny subretinal chip, paired with glasses, that helps people with age-related macular degeneration recover some vision. The device is approved in Europe and available in Germany, with further European rollouts reported to follow, and the company is now trialing it for a second blindness-causing condition, Stargardt disease. The new funding is aimed at the US market: Science is pursuing approval through the FDA’s Humanitarian Device Exemption pathway, which covers medical technology for rare conditions, after convincing the agency that advanced macular degeneration in both eyes qualifies.

The longer game

PRIMA is the near-term business, but Science’s founding ambition is bigger: a bio-hybrid sensor that connects directly to the brain, built from cultured neurons combined with silicon. The company is designing initial human trials of that platform with Yale neurosurgery professor Murat Günel, and has said it could eventually offer treatments for conditions such as Parkinson’s disease. That is years-from-market research, and it should be read as such — today’s valuation rests on the vision business, not the brain interface.

Why it matters

Brain-computer interfaces have mostly traded on demos and promises. Science is the unusual case of a BCI company with a regulated, shipping product and a defined US approval path, which is exactly what a $3.5 billion price tag needs underneath it. The open questions are the normal hard ones: how the FDA process goes, how many patients PRIMA actually reaches, and whether the bio-hybrid brain work ever leaves the lab. Everything AI, tested — this is real hardware helping real patients today, with the speculative part clearly labeled as speculative.

Frequently asked questions

Who founded Science Corporation?

Max Hodak, the former president of Neuralink, founded Science Corporation in 2021 to build technologies that interact directly with the brain.

What is PRIMA?

PRIMA is Science’s first product: a subretinal implant used with glasses that restores some vision in people with age-related macular degeneration. It is approved in Europe and available in Germany.

When is PRIMA coming to the United States?

Science is seeking US approval through the FDA’s Humanitarian Device Exemption pathway; the company has not announced an approval date.

Sources: TechCrunch, Science Corporation announcement, Bloomberg via BigGo Finance

Leave a Comment

Your email address will not be published. Required fields are marked *

Get the 5 best AI tools every week

Top AI news, tools, and prompts — one short email. Free, unsubscribe anytime.

Run a newsletter of your own? Monetize and grow it with SparkLoop →

Scroll to Top